Holen Sie sich die Stockscreener-App
4.03
0.25%
0.04
Handel nachbörslich:
4.04
0.010
+0.25%
Schlusskurs vom Vortag:
$3.99
Offen:
$4
24-Stunden-Volumen:
309.55K
Relative Volume:
2.00
Marktkapitalisierung:
$164.93M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$63.21M
KGV:
2.7133
EPS:
1.4853
Netto-Cashflow:
$-9.71M
1W Leistung:
-7.62%
1M Leistung:
+3.90%
6M Leistung:
+40.35%
1J Leistung:
+88.68%
1-Tages-Spanne:
$3.87
$4.145
1-Wochen-Bereich:
$3.87
$4.43
52-Wochen-Spanne:
$1.975
$5.01
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.03 | 163.30M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy - openPR.com
Oramed Pharmaceuticals (ORMP) Drops 8.9%: Support Level Under PressureInitial Balance - Newser
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha
ORMP Should I Buy - Intellectia AI
Oramed Pharmaceuticals Inc. Q1 2026 Financial Report: Key Investments, Marketable Securities, and Forward-Looking Statements - Minichart
Oramed: Q1 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary - TradingView
Oramed (NASDAQ: ORMP) swings to $38.3M Q1 profit on Alpha Tau and Scilex gains - Stock Titan
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifeward Ltd.16079622026 - SEC.gov
Oramed Pharmaceuticals (ORMP) Q4 2025 Financial OverviewIncome Pick - newser.com
Oramed Pharmaceuticals Delays Quarterly SEC Filing - TipRanks
Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing - Stock Titan
About Us | Oil & Gas JournalOramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Stock Quote - FinancialContent
Oramed Pharmaceuticals (ORMP) Stock: Slides -0.74%, Support at $4.46 2026-05-15Buy Signals - newser.com
Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G - Stock Titan
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Oramed Pharmaceuticals stock (US68403P1003): Oral drug delivery innovator for US diabetes market - AD HOC NEWS
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks - Yahoo Finance
Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30 - AD HOC NEWS
TradingKey - TradingKey
MSN Money - MSN
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
ORMP (Oramed Pharmaceuticals) falls 2.84% after releasing Q4 2025 earnings with no prior analyst consensus estimates.Current Ratio - Xã Thanh Hà
ORMP (Oramed Pharmaceuticals Inc.) rises 0.53 percent following release of its 2025 fourth quarter earnings results.Debt/Equity - Xã Thanh Hà
Oramed Pharmaceuticals (ORMP) Stock Rally Stalls (+1.05%) 2026-04-16Shared Momentum Picks - Xã Vĩnh Công
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Sell Signal: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Overview Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fund Flows: Can Oramed Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Technical Analysis: Will Oramed Pharmaceuticals Inc face regulatory challenges2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
INO Stock Analysis: Inovio Pharmaceuticals Inc. plunges 35% to $1.13 biotech support level - Xã Thanh Hà
ORMP Q4 Earnings: Beats Estimates by $1.16 - newser.com
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):